The University of Southampton
University of Southampton Institutional Repository

Relevance of brain-derived neurotrophic factor levels in schizophrenia: A systematic review and meta-analysis

Relevance of brain-derived neurotrophic factor levels in schizophrenia: A systematic review and meta-analysis
Relevance of brain-derived neurotrophic factor levels in schizophrenia: A systematic review and meta-analysis

Background: Brain Derived Neurotrophic Factor (BDNF) is one of the neuromodulators crucial for the survival, development and function of neurones in the brain and nervous system. Several authors linked its changes in production and concentration to Schizophrenia syndromes. Aim: This systematic review examined the available evidence to clarify the association between plasma BDNF levels and Schizophrenia. Method: Initial searches revealed 266 records. After screening of abstracts, 20 studies were selected. Following a preliminary review, 14 studies were included in this systematic review and meta-analysis. Results: Of the 14 studies (910 patients, 717 controls) 8 reported decreased BDNF levels in patients with schizophrenia as compared to controls; 3 studies (274/128) found increased BDNF levels; while 3 (62/62) reported no group differences. Meta-analysis of all pooled studies confirmed reduced BDNF levels in schizophrenia versus controls (medium effect size); however, the group difference was not significant when studies using unmedicated cases were considered. Conclusion: The cumulative evidence indicates reduced BDNF levels existing in schizophrenia. However, findings are less clear in unmedicated cases, suggesting that reduced BDNF levels in schizophrenia may be associated with symptom chronicity and/or chronic effects of antipsychotic medication.

BDNF, Brain derived neurotrophic factor, Development, Function, Levels, Neuromodulator, Neurones, Plasma, Schizophrenia, Serum
2373-7972
280-293
Rowbotham, Ian M.
c25f7d26-aa7f-4338-bcee-07fb912d6c98
Orsucci, Franco F.
b3af845c-dfad-4b5f-a5fd-a8e57d9d0d6f
Mansour, Mohamed F.
a202dd0a-a5a1-4009-9583-bab931fbcad1
Chamberlain, Samuel R.
8a0e09e6-f51f-4039-9287-88debe8d8b6f
Raja, Haroon Y.
dd81f344-c7d5-4dd8-8bf9-b73849ec8fb3
Rowbotham, Ian M.
c25f7d26-aa7f-4338-bcee-07fb912d6c98
Orsucci, Franco F.
b3af845c-dfad-4b5f-a5fd-a8e57d9d0d6f
Mansour, Mohamed F.
a202dd0a-a5a1-4009-9583-bab931fbcad1
Chamberlain, Samuel R.
8a0e09e6-f51f-4039-9287-88debe8d8b6f
Raja, Haroon Y.
dd81f344-c7d5-4dd8-8bf9-b73849ec8fb3

Rowbotham, Ian M., Orsucci, Franco F., Mansour, Mohamed F., Chamberlain, Samuel R. and Raja, Haroon Y. (2015) Relevance of brain-derived neurotrophic factor levels in schizophrenia: A systematic review and meta-analysis. AIMS Neuroscience, 2 (4), 280-293. (doi:10.3934/Neuroscience.2015.4.280).

Record type: Review

Abstract

Background: Brain Derived Neurotrophic Factor (BDNF) is one of the neuromodulators crucial for the survival, development and function of neurones in the brain and nervous system. Several authors linked its changes in production and concentration to Schizophrenia syndromes. Aim: This systematic review examined the available evidence to clarify the association between plasma BDNF levels and Schizophrenia. Method: Initial searches revealed 266 records. After screening of abstracts, 20 studies were selected. Following a preliminary review, 14 studies were included in this systematic review and meta-analysis. Results: Of the 14 studies (910 patients, 717 controls) 8 reported decreased BDNF levels in patients with schizophrenia as compared to controls; 3 studies (274/128) found increased BDNF levels; while 3 (62/62) reported no group differences. Meta-analysis of all pooled studies confirmed reduced BDNF levels in schizophrenia versus controls (medium effect size); however, the group difference was not significant when studies using unmedicated cases were considered. Conclusion: The cumulative evidence indicates reduced BDNF levels existing in schizophrenia. However, findings are less clear in unmedicated cases, suggesting that reduced BDNF levels in schizophrenia may be associated with symptom chronicity and/or chronic effects of antipsychotic medication.

This record has no associated files available for download.

More information

Published date: 2015
Additional Information: Publisher Copyright: © 2015 Ian M Rowbotham et al.
Keywords: BDNF, Brain derived neurotrophic factor, Development, Function, Levels, Neuromodulator, Neurones, Plasma, Schizophrenia, Serum

Identifiers

Local EPrints ID: 492972
URI: http://eprints.soton.ac.uk/id/eprint/492972
ISSN: 2373-7972
PURE UUID: 3c65c207-d5c8-437f-bc62-2e2647a89b65
ORCID for Samuel R. Chamberlain: ORCID iD orcid.org/0000-0001-7014-8121

Catalogue record

Date deposited: 21 Aug 2024 17:04
Last modified: 22 Aug 2024 02:01

Export record

Altmetrics

Contributors

Author: Ian M. Rowbotham
Author: Franco F. Orsucci
Author: Mohamed F. Mansour
Author: Samuel R. Chamberlain ORCID iD
Author: Haroon Y. Raja

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×